Related Experiment Video
Updated: Dec 5, 2025

05:16
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
7.2K
Sarepta Duchenne Muscular Dystrophy Candidate Faces U.S. Food and Drug Administration Assay Request, Patent Suit
1Mary Ann Liebert, Inc., Publishers, New Rochelle, New York, USA.
Human Gene Therapy
|October 19, 2020
Abstract
No abstract available in PubMed .
Related Concept Videos
Satellite Stem Cells and Muscular Dystrophy
2.2K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.2K
Drug Products: Biologics, Biosimilars and Interchangeables
145
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
145
FDA Approved Drugs: Changes to Approved Drugs
106
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
106

